Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 1

Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors,  or both? Expectations from The ONTARGET  Trial Programme

       
Total article views   HTML views PDF downloads Totals
10,293 Dovepress* 7,303+ 348 7,651
PubMed Central* 2,990 157 3,147
Totals 10,293 505 10,798
*Since 15 March 2007
+Since July 2016

View citations on PubMed Central and Google Scholar